What is the debt of Imugene this year?
Imugene has a debt level of -11.28 AUD this year.
Imugene Debt 2025
Imugene Debt
-11.28 AUD
Ticker
IMU.AX
ISIN
AU000000IMU9
WKN
891460
In 2025, Imugene's total debt was -11.28 AUD, a -92.61% change from the -152.6 AUD total debt recorded in the previous year.
Imugene Aktienanalyse
What does Imugene do?
Imugene Ltd is an Australian biotechnology company focused on the development of immunotherapies for various diseases, including cancer and infectious diseases. The company was founded in 2014 and is headquartered in Sydney. Imugene's business model is based on collaboration with academic institutions and other biotechnology companies to identify and develop promising drug candidates. The company also works closely with clinical researchers and physicians to accelerate drug development and ensure they meet patient needs. Imugene specializes in four different areas: oncology, immunology, infectious diseases, and neuroscience. Each area focuses on the development of drugs for specific diseases and medical needs. In the field of oncology, Imugene is focused on developing immunotherapy products for the treatment of breast cancer, colon cancer, lung cancer, and other types of cancer. Immunotherapy aims to strengthen the body's immune system to better destroy cancer cells. In the field of immunology, Imugene is focused on developing immunotherapy products for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immunotherapy aims to modulate the immune system to eliminate disease-causing cells. In the field of infectious diseases, Imugene is focused on developing vaccines and products for the treatment of diseases such as COVID-19, influenza, hepatitis B, and HPV. Vaccines aim to activate the immune system to recognize and destroy pathogens before they can cause harm in the body. In the field of neuroscience, Imugene is focused on developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. These drugs aim to stimulate the brain's neuroprotective mechanisms to reduce nerve damage. Imugene has several promising products in the pipeline that aim to demonstrate the efficacy and safety of immunotherapy and other therapies. The company has already conducted clinical trials for some of these products, while others are still in preclinical development. One of Imugene's key products is HER-Vaxx, a vaccine for the treatment of breast cancer that activates the body's immune system against the HER2 protein, which promotes cancer growth in some individuals. The vaccine has been tested in clinical trials and has shown promising results. Another promising product from Imugene is PD1-Vaxx, a vaccine for the treatment of lung cancer that targets the activation of an important immune cell sensor. Preliminary study results suggest that treatment with PD1-Vaxx is synergistic with checkpoint inhibitors, another type of cancer treatment medication. Imugene is also working on a range of products for the treatment of COVID-19, including IMM-013, a vaccine against SARS-CoV-2, and IMM-036, an antibody against the virus. These products are being tested in preclinical development and are aimed at helping to contain the spread of the pandemic. Overall, Imugene aims to develop innovative drugs for the treatment of various medical needs. The company relies on close collaboration with academic and clinical partners to accelerate drug development and ensure its products meet the highest standards of efficacy and safety. Imugene ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Imugene's Debt Structure
Imugene's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Imugene's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Imugene’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Imugene’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Imugene stock
What was the debt of Imugene compared to the previous year?
The debt of Imugene has increased by -92.61% compared to the previous year dropped.
What are the consequences of high debt for investors in Imugene?
High debt can pose a risk for investors of Imugene, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Imugene?
Low debt means that Imugene has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Imugene affect the company?
An increase in debt of Imugene can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Imugene affect the company?
A reduction in debt of Imugene can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Imugene?
Some factors that can influence the debt of Imugene include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Imugene so important for investors?
The debts of Imugene are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Imugene take to change the debt?
To change the debt, Imugene can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Imugene pay?
Over the past 12 months, Imugene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Imugene is expected to pay a dividend of 0 AUD.
What is the dividend yield of Imugene?
The current dividend yield of Imugene is .
When does Imugene pay dividends?
Imugene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Imugene?
Imugene paid dividends every year for the past 0 years.
What is the dividend of Imugene?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Imugene located?
Imugene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Imugene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Imugene from 9/26/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.
When did Imugene pay the last dividend?
The last dividend was paid out on 9/26/2025.
What was the dividend of Imugene in the year 2024?
In the year 2024, Imugene distributed 0 AUD as dividends.
In which currency does Imugene pay out the dividend?
The dividends of Imugene are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Imugene
Our stock analysis for Imugene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imugene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
